Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Shield CA Genetic Testing Coverage | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Shield of CaliforniaPolicy 2.04.151

    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer

    Customize your policy alerts

    Sign up for blue_shield_of_california Policy 2.04.151 alerts

    Get alerted when Policy 2.04.151 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of tissue, blood, bone marrow, and liquid-biopsy genetic or molecular testing used to select FDA-approved targeted treatments for specified advanced cancers.

    Policy Summary
    PayerBlue Shield of California
    PolicyGenetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer
    Policy CodePolicy 2.04.151
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument the cancer diagnosis, disease status, intended therapy, relevant biomarker or variant, and tissue status when submitting a testing request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20Testing indication groups
    FDA-approved targeted therapyCovered testing purpose
    FDA-approved testRequired test standard
    Somatic and germline testingTesting modalities
    RET plasma testingExplicitly investigational use

    Coverage Criteria

    ALK Testing

    Covered when ALL of the following are met.

    ALK testing: Tumor-tissue somatic ALK rearrangement testing for advanced lung adenocarcinoma or cancer in which an adenocarcinoma component cannot be excluded; used to select an FDA-approved ALK inhibitor; no FDA-labeled contraindication and use consistent with the FDA-approved label.

    BRAF V600E Testing

    Covered when ALL of the following are met.

    BRAF V600E testing: Tumor-tissue somatic BRAF V600E testing for advanced lung adenocarcinoma, colorectal cancer, glioma, anaplastic thyroid cancer, or unresectable/metastatic or resected stage III melanoma; used to select FDA-approved BRAF and/or MEK inhibitor therapy; no FDA-labeled contraindication and use consistent with the FDA-approved label.

    BRAF V600 or Fusion Testing in Pediatric Low-Grade Glioma

    Covered when BOTH of the following are met.

    Policy Summary
    PayerBlue Shield of California
    PolicyGenetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer
    Policy CodePolicy 2.04.151
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument the cancer diagnosis, disease status, intended therapy, relevant biomarker or variant, and tissue status when submitting a testing request.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications and Evidence-Based UsesCoding and Companion Diagnostic IdentifiersProvider Actions and Review RequirementsBackgroundDefinitionsEligibility RequirementsNot Covered and Investigational Uses
    Pediatric low-grade glioma BRAF testing: BRAF V600 variant or BRAF fusion rearrangement testing in relapsed or refractory pediatric low-grade glioma; used to select tovorafenib.

    Germline BRCA1 and BRCA2 Testing

    Covered when BOTH of the following are met.

    Germline BRCA1/BRCA2 testing: Germline BRCA1 or BRCA2 testing for HER2-negative metastatic or early-stage high-risk breast cancer, metastatic castration-resistant prostate cancer, or advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; used to select a PARP inhibitor.

    Somatic BRCA1 and BRCA2 Testing

    Covered when BOTH of the following are met.

    Somatic BRCA1/BRCA2 testing: Tumor-tissue somatic BRCA1/2 testing for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, or metastatic castration-resistant prostate cancer; used to select FDA-approved targeted therapy.

    CLDN18 Testing

    Covered when BOTH of the following are met.

    CLDN18 testing for locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors determined by an FDA-approved test; used to select FDA-approved targeted therapy.

    EGFR Exons 18-21 Testing

    Covered when ALL of the following are met.

    EGFR exons 18-21 testing: Tumor-tissue somatic EGFR exon 18 through 21 testing for advanced lung adenocarcinoma, large-cell carcinoma, advanced squamous-cell NSCLC, or NSCLC not otherwise specified; used to select FDA-approved therapy; no contraindication and FDA-label-consistent use.

    EGFR Exon 20 Testing

    Covered when ALL of the following are met.

    EGFR exon 20 testing: Tumor-tissue somatic EGFR exon 20 testing, including insertion mutations, for NSCLC; used to select FDA-approved therapy; no contraindication and FDA-label-consistent use.

    EGFR Testing in Metastatic Colorectal Cancer

    Covered when ALL of the following are met.

    EGFR colorectal cancer testing: Tumor-tissue somatic EGFR testing for metastatic colorectal cancer; used to select FDA-approved targeted therapy; no contraindication and FDA-label-consistent use.

    ESR1 Testing

    Covered when ALL of the following are met.

    ESR1 tissue testing: Tissue somatic ESR1 testing as an alternative to liquid biopsy for estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with progression after at least one line of endocrine therapy; used to select elacestrant; no contraindication and FDA-label-consistent use.

    EZH2 Testing

    Covered when ALL of the following are met.

    EZH2 testing: FDA-approved tumor-tissue EZH2 testing for relapsed or refractory follicular lymphoma after at least two prior systemic therapies; used to select tazemetostat.

    FGFR2 Testing

    Covered when ALL of the following are met.

    FGFR2 testing: FDA-approved tumor-tissue FGFR2 testing for previously treated unresectable locally advanced or metastatic cholangiocarcinoma; used to select pemigatinib.

    FGFR3 Testing

    Covered when ALL of the following are met.

    FGFR3 testing: Tumor-tissue FGFR3 testing for locally advanced or metastatic urothelial carcinoma after progression during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant therapy; used to select erdafitinib.

    FLT3 Testing

    Covered when ALL of the following are met.

    FLT3 testing: FDA-approved FLT3 variant or ITD testing using blood or bone marrow for acute myeloid leukemia; used to select FDA-approved targeted therapy; no contraindication and FDA-label-consistent use.

    FOLR1 Testing

    Covered when ALL of the following are met.

    FOLR1 testing: Tumor-tissue FOLR1 testing for epithelial ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant after one to three prior systemic regimens; used to select FDA-approved targeted therapy.

    HER2 Testing

    Covered when BOTH of the following are met.

    HER2 testing: Tumor-tissue HER2 testing for metastatic solid tumors; used to select FDA-approved therapy.

    Homologous Recombination Repair Gene Testing

    Covered when BOTH of the following are met.

    Somatic HRR gene testing: Tissue-biopsy somatic testing for BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L variants in metastatic castration-resistant prostate cancer; used to select FDA-approved targeted therapy.

    Homologous Recombination Deficiency Testing

    Covered when BOTH of the following are met.

    HRD testing: Tumor-tissue homologous recombination deficiency analysis for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; used to select FDA-approved targeted therapy.

    HLA Testing

    Covered when BOTH of the following are met.

    HLA testing: Tumor-tissue HLA testing for unresectable or metastatic uveal melanoma; used to select tebentafusp-tebn.

    Homologous recombination deficiency testing

    Covered when BOTH criteria are met.

    HRD testing: Tumor-tissue HRD analysis for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to select FDA-approved targeted therapy.

    HLA testing

    Covered when BOTH criteria are met.

    HLA testing: Tumor-tissue HLA testing for unresectable or metastatic uveal melanoma to select tebentafusp-tebn (Kimmtrak).

    IDH1/IDH2 testing for glioma

    Covered when ALL criteria are met.

    IDH1/IDH2 glioma testing: Tumor-tissue IDH1 or IDH2 testing for glioma, including grade 2 astrocytoma or oligodendroglioma, following biopsy, subtotal resection, or gross total resection; used to select vorasidenib.

    IDH1/IDH2 testing for acute myeloid leukemia

    Covered when BOTH criteria are met.

    IDH1/IDH2 AML testing: IDH1 or IDH2 testing for relapsed or refractory AML, AML in an individual age 75 years or older, or newly diagnosed AML with comorbidities precluding intensive induction chemotherapy; used to select FDA-approved therapy consistent with its label.

    IDH1 testing for MDS or cholangiocarcinoma

    Covered when BOTH criteria are met.

    IDH1 testing for relapsed or refractory myelodysplastic syndromes or locally advanced/metastatic cholangiocarcinoma; used to select ivosidenib consistent with its labeled indication.

    KIT D816V testing

    Covered when BOTH criteria are met.

    KIT D816V testing for aggressive systemic mastocytosis; used to select imatinib mesylate.

    KMT2A testing

    Covered when BOTH criteria are met.

    KMT2A testing: Tumor-tissue somatic KMT2A rearrangement testing for relapsed or refractory AML; used to select revumenib.

    MET exon 14 skipping alteration testing

    Covered when ALL criteria are met.

    MET exon 14 skipping testing: Tumor-tissue testing for alterations leading to MET exon 14 skipping in metastatic NSCLC; used to select capmatinib; no FDA-labeled contraindication and FDA-label-consistent use.

    Mismatch repair/microsatellite instability testing

    Covered when ALL criteria are met.

    Mismatch repair/MSI testing: Tumor-tissue mismatch repair or microsatellite instability testing for unresectable or metastatic solid tumors; used to select an FDA-approved immune checkpoint inhibitor with an NCCN recommendation of 2A or higher; no contraindication and FDA-label-consistent use.

    NTRK testing for recurrent or stage IV breast cancer

    Covered when BOTH criteria are met.

    NTRK breast cancer testing: NTRK fusion testing for recurrent unresectable local/regional or stage IV breast cancer; used to select FDA-approved therapy.

    NTRK fusion testing

    Covered when ALL criteria are met.

    NTRK fusion testing: Tumor-tissue NTRK fusion testing for metastatic NSCLC, metastatic colorectal cancer, unresectable/metastatic melanoma, glioma, advanced epithelial ovarian/fallopian tube/primary peritoneal cancer, or other advanced solid tumors; used to select larotrectinib or entrectinib; no contraindication and FDA-label-consistent use.

    PDGFRA testing

    Covered when BOTH criteria are met.

    PDGFRA testing: Tumor-tissue PDGFRA testing, such as D842V, for unresectable or metastatic gastrointestinal stromal tumor; used to select avapritinib.

    PDGFRB testing

    Covered when BOTH criteria are met.

    PDGFRB testing: Tumor-tissue PDGFRB rearrangement testing, such as FIP1L1PDGFR, for myelodysplastic or myeloproliferative disease; used to select imatinib mesylate.

    PIK3CA testing

    Covered when ALL criteria are met.

    PIK3CA testing for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer that progressed on or after an endocrine-based regimen; used to select alpelisib.

    PD-L1 testing

    Covered when ALL criteria are met.

    PD-L1 testing: Tumor-tissue PD-L1 testing for unresectable or metastatic solid tumors; used to select an FDA-approved immune checkpoint inhibitor with an NCCN recommendation of 2A or higher; no contraindication and FDA-label-consistent use.

    KRAS testing for lung cancer

    Covered when ALL criteria are met.

    KRAS lung cancer testing: Tumor-tissue somatic KRAS testing, such as G12C, for advanced lung adenocarcinoma or cancer in which an adenocarcinoma component cannot be excluded; used to select sotorasib; no contraindication and FDA-label-consistent use.

    KRAS and NRAS testing for colorectal cancer

    Covered when BOTH criteria are met.

    KRAS/NRAS colorectal cancer testing: Tumor-tissue KRAS and NRAS testing for metastatic colorectal cancer; used to select FDA-approved therapy.

    RET testing

    Covered when ALL criteria are met.

    RET testing: Tumor-tissue somatic RET testing for advanced or metastatic NSCLC, colorectal cancer, medullary thyroid cancer, thyroid cancer, or other solid tumors; used to select pralsetinib or selpercatinib; no contraindication and FDA-label-consistent use.

    ROS1 testing

    Covered when ALL criteria are met.

    ROS1 testing: Tumor-tissue somatic ROS1 rearrangement testing for advanced lung adenocarcinoma or cancer in which an adenocarcinoma component cannot be excluded; used to select an FDA-approved ROS1 inhibitor; no contraindication and FDA-label-consistent use.

    TP53 testing

    Covered when BOTH criteria are met.

    TP53 testing: Tumor-tissue testing for somatic deletion of chromosome 17p involving TP53 in chronic lymphocytic leukemia; used to select venetoclax.

    Tumor mutational burden testing

    Covered when ALL criteria are met.

    TMB testing: Tumor-tissue TMB testing for unresectable or metastatic solid tumors; used to select an FDA-approved immune checkpoint inhibitor with an NCCN recommendation of 2A or higher; no contraindication and FDA-label-consistent use.

    ALK liquid biopsy testing

    Covered when ALL criteria are met; plasma testing is an alternative to tissue biopsy.

    Plasma ALK testing: Plasma ALK rearrangement testing for NSCLC using an FDA-approved companion diagnostic to detect ctDNA; used to select an FDA-approved ALK inhibitor; no contraindication and FDA-label-consistent use for the agent and test.

    BRAF V600E liquid biopsy testing

    Covered when ALL criteria are met; plasma testing is an alternative to tissue biopsy.

    Plasma BRAF V600E testing for metastatic colorectal cancer or metastatic NSCLC using an FDA-approved companion diagnostic to detect ctDNA; used to select FDA-approved therapy; no contraindication and FDA-label-consistent use.

    Other somatic biomarker analysis

    Not covered as medically necessary; considered investigational.

    Unlisted somatic biomarker testing: Somatic biomarker analysis used to select targeted therapy outside the listed indications or Table 1 uses in unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer.

    Tumor mutational burden tissue testing

    May be considered medically necessary when ALL criteria are met.

    TMB tissue testing: Unresectable or metastatic solid tumor; testing used to select an FDA-approved immune checkpoint inhibitor with an NCCN recommendation of 2A or higher; no FDA-labeled contraindication and FDA-label-consistent use.

    ALK plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    ALK plasma testing: NSCLC; FDA-approved companion diagnostic plasma test detects ALK ctDNA; testing selects an FDA-approved ALK inhibitor; no contraindication and FDA-label-consistent use.

    BRAF V600E plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    BRAF V600E plasma testing: Metastatic colorectal cancer or metastatic NSCLC; FDA-approved companion diagnostic plasma test detects ctDNA; testing selects FDA-approved therapy; no contraindication and FDA-label-consistent use.

    BRCA1/2 ctDNA testing

    May be considered medically necessary when BOTH criteria are met.

    BRCA1/2 ctDNA testing: Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; testing selects FDA-approved targeted therapy when tissue-based analysis is not clinically feasible.

    EGFR exon 19-21 plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    EGFR exon 19-21 plasma testing: Eligible advanced lung cancer or NSCLC; testing at diagnosis with an FDA-approved companion diagnostic plasma test for EGFR ctDNA; used to select FDA-approved therapy; no contraindication and FDA-label-consistent use.

    EGFR T790M plasma testing

    May be considered medically necessary when ALL criteria are met.

    EGFR T790M plasma testing: Eligible advanced lung cancer or NSCLC at progression; FDA-approved companion diagnostic plasma test; tissue biopsy is not feasible because tissue is insufficient, no biopsy-amenable lesion exists, or biopsy cannot be performed; testing selects osimertinib; no contraindication and FDA-label-consistent use.

    ESR1 testing

    May be considered medically necessary when ALL criteria are met.

    ESR1 ctDNA testing: Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer; FDA-approved companion diagnostic test detects tumor DNA; testing predicts response to elacestrant or camizestrant.

    BRCA1, BRCA2, and ATM ctDNA testing

    May be considered medically necessary when BOTH criteria are met.

    BRCA1/2/ATM ctDNA testing: Metastatic castration-resistant prostate cancer; testing selects FDA-approved targeted therapy.

    MET plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    MET plasma testing: NSCLC; FDA-approved companion diagnostic plasma test detects ctDNA; testing selects MET inhibitor therapy such as capmatinib; no contraindication and FDA-label-consistent use.

    NTRK plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    NTRK plasma testing: Eligible advanced or metastatic cancer; FDA-approved companion diagnostic plasma test detects NTRK ctDNA; testing selects TRK inhibitor therapy such as larotrectinib or entrectinib; no contraindication and FDA-label-consistent use.

    PIK3CA testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    PIK3CA ctDNA testing: Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with progression on or after endocrine therapy; testing selects alpelisib.

    KRAS plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when ALL criteria are met.

    KRAS plasma testing: Advanced lung adenocarcinoma or cancer in which an adenocarcinoma component cannot be excluded; FDA-approved companion diagnostic plasma test detects ctDNA; testing selects sotorasib; no contraindication and FDA-label-consistent use.

    ROS1 plasma testing

    May be considered medically necessary as an alternative to tissue biopsy when BOTH criteria are met.

    ROS1 plasma testing: NSCLC; testing selects ROS1 inhibitor therapy such as crizotinib or entrectinib.

    Plasma testing due to insufficient tissue

    May be considered medically necessary when BOTH criteria are met.

    Plasma testing when tissue is insufficient: Insufficient formalin-fixed paraffin-embedded tissue for standard molecular testing; follow-up tissue analysis planned if plasma testing identifies no driver variant.

    Biomarker testing for targeted therapy

    Testing is supported for patients who meet the described cancer and treatment-selection conditions.

    Targeted-treatment biomarker testing: Unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer; patient is being considered for an FDA-approved targeted drug consistent with its labeled indication; therapy has an NCCN recommendation of 2A or higher.

    California statutory coverage requirement

    California law requires coverage when prescribed for the specified clinical purposes.

    California biomarker-testing coverage: Biomarker testing is prescribed to diagnose, treat, appropriately manage, or provide ongoing monitoring of an enrollee's disease or condition to guide treatment decisions.

    BRAF testing in glioma is limited to the specified pediatric indication. Testing for BRAF V600 variants or BRAF fusion rearrangements, such as KIAA1549::BRAF, may be considered medically necessary when the individual has relapsed or refractory pediatric low-grade glioma and testing is used to select tovorafenib. Testing for these variants to select targeted treatment in all other individuals with glioma is considered investigational.

    Unlisted somatic biomarker analysis is investigational. Genetic biomarker analysis for somatic variants used to select treatment with an FDA-approved targeted therapy is considered investigational when the use is not among the policy’s listed indications or the uses identified in Table 1, including testing for individuals with unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer.

    Inherited cancer-risk testing is outside the scope of this policy. This policy does not address germline testing performed to assess an individual’s inherited risk of developing cancer. Such testing is addressed separately under applicable genetic-testing policies.

    Plasma RET alteration testing is investigational as an alternative to tissue biopsy. This limitation applies when plasma circulating tumor DNA testing is used to identify somatic RET alterations for selection of RET inhibitor therapy in advanced or metastatic NSCLC, colorectal cancer, medullary or other thyroid cancer, or any other solid tumor.

    Other somatic ctDNA uses are investigational. Except for the liquid-biopsy indications specifically addressed in the policy, somatic circulating tumor DNA testing used to guide cancer-targeted therapy is considered investigational.

    Off-label or off-study treatment use is not recommended in the stated circumstances. Use of a genomic biomarker-linked therapy approved for another disease is not recommended when a clinical trial is available or when there is no clinical evidence of meaningful efficacy.

    Covered Indications and Evidence-Based Uses

    ALK rearrangement companion diagnostic testing

    The table associates FDA-approved companion diagnostic testing with targeted treatment when the corresponding biomarker is present.

    ALK companion diagnosis: NSCLC testing identifies an ALK rearrangement using listed companion diagnostic testing and supports Alecensa, Xalkori, or Zykadia.

    Other NSCLC companion diagnostic associations

    The table lists additional biomarker-test-treatment associations for NSCLC.

    Listed NSCLC biomarkers: FDA-approved assay identifies EGFR, KRAS G12C, ERBB2, MET exon 14, BRAF V600E, ROS1, RET, or PD-L1 for associated targeted or immune therapy.

    Genetic variant testing for FDA-approved targeted therapies

    Evidence reviewed for testing to select an FDA-approved targeted therapy.

    Advanced cancer targeted-therapy testing: Unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer; FDA-approved targeted drug is being considered consistent with its labeled indication; evidence includes therapies with NCCN recommendations of 2A or higher.

    ASCO advanced solid-tumor genomic testing

    ASCO genomic testing framework.

    Actionable genomic testing: For metastatic or advanced solid tumors with adequate performance status, test when a genomic biomarker-linked therapy is approved, when genomic biomarker-based contraindications or exclusions must be evaluated, when a fusion-targeted therapy is approved, or when no driver is identified on large-panel DNA sequencing and fusion testing is needed.

    CMS NGS coverage criteria

    CMS national coverage requirements for NGS diagnostic laboratory testing.

    CMS patient eligibility: Recurrent, relapsed, refractory, metastatic, or advanced stage III/IV cancer; same NGS test and cancer genetic content not previously performed; patient has decided to seek further treatment.
    CMS test requirements: Test is performed in a CLIA-certified laboratory; has FDA approval or clearance as a companion in vitro diagnostic and an FDA-approved or cleared indication for the patient's cancer; results are reported to the treating physician in a treatment-options template.

    Somatic ALK rearrangement testing in advanced lung adenocarcinoma

    Covered when ALL of the following are met.

    Somatic ALK rearrangement testing in tumor tissue for advanced lung adenocarcinoma or cancer in which an adenocarcinoma component cannot be excluded; used to select an FDA-approved ALK inhibitor; no contraindication and FDA-label-consistent use.

    Somatic BRAF V600E testing for specified cancers

    Covered when ALL of the following are met.

    Somatic BRAF V600E tumor testing for specified advanced lung, colorectal, thyroid, melanoma, or glioma indications; used to select FDA-approved BRAF and/or MEK inhibitor therapy; no contraindication and FDA-label-consistent use.

    Pediatric low-grade glioma BRAF testing

    Covered when BOTH of the following are met.

    BRAF V600 variant or fusion rearrangement testing in relapsed or refractory pediatric low-grade glioma; used to select tovorafenib.

    Germline BRCA1 or BRCA2 testing

    Covered when BOTH of the following are met.

    Germline BRCA1 or BRCA2 testing for specified high-risk breast, metastatic castration-resistant prostate, or advanced gynecologic cancer; used to select PARP inhibitor therapy.

    Somatic BRCA1/2 testing

    Covered when BOTH of the following are met.

    Somatic BRCA1/2 testing using tumor tissue for advanced gynecologic cancer or metastatic castration-resistant prostate cancer; used to select FDA-approved targeted therapy.

    CLDN18 testing

    Covered when BOTH of the following are met.

    CLDN18 testing for locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors determined by an FDA-approved test; used to select FDA-approved targeted therapy.

    Somatic EGFR testing

    Covered when ALL of the following are met.

    Somatic EGFR testing in tumor tissue for the specified advanced lung cancers, NSCLC, or metastatic colorectal cancer, with applicable exon-specific criteria; used to select FDA-approved targeted therapy; no contraindication and FDA-label-consistent use.

    Tissue somatic ESR1 testing

    Covered when ALL of the following are met.

    Tissue somatic ESR1 testing as an alternative to liquid biopsy for estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer after progression on at least one line of endocrine therapy; used to select elacestrant; no contraindication and FDA-label-consistent use.

    EZH2 testing

    Covered when ALL of the following are met.

    FDA-approved tumor-tissue EZH2 testing for relapsed or refractory follicular lymphoma after at least two prior systemic therapies; used to select tazemetostat.

    FGFR2 testing

    Covered when ALL of the following are met.

    FDA-approved tumor-tissue FGFR2 testing for previously treated unresectable locally advanced or metastatic cholangiocarcinoma; used to select pemigatinib.

    FGFR3 testing

    Covered when ALL of the following are met.

    Tumor-tissue FGFR3 testing for locally advanced or metastatic urothelial carcinoma after progression during or following platinum-containing chemotherapy; used to select erdafitinib.

    FLT3 testing

    Covered when ALL of the following are met.

    FDA-approved FLT3 testing using blood or bone marrow for AML; used to select FDA-approved targeted therapy; no contraindication and FDA-label-consistent use.

    FOLR1 testing

    Covered when ALL of the following are met.

    Tumor-tissue FOLR1 testing for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens; used to select FDA-approved targeted therapy.

    HER2 testing

    Covered when BOTH of the following are met.

    Tumor-tissue HER2 testing for metastatic solid tumors; used to select FDA-approved therapy.

    Somatic HRR gene testing

    Covered when BOTH of the following are met.

    Somatic HRR gene testing using tissue biopsy for metastatic castration-resistant prostate cancer; includes BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L; used to select FDA-approved targeted therapy.

    HRD analysis

    Covered when BOTH of the following are met.

    Tumor-tissue HRD analysis for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; used to select FDA-approved targeted therapy.

    HLA testing

    Covered when BOTH of the following are met.

    Tumor-tissue HLA testing for unresectable or metastatic uveal melanoma; used to select tebentafusp-tebn.

    Tumor-tissue HRD analysis

    Covered when BOTH of the following are met.

    Tumor-tissue HRD analysis for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to select FDA-approved targeted therapy.

    Tumor-tissue HLA testing

    Covered when BOTH of the following are met.

    Tumor-tissue HLA testing for unresectable or metastatic uveal melanoma to select tebentafusp-tebn.

    IDH1/IDH2 tumor testing

    Covered when applicable criteria are met.

    IDH1/IDH2 tumor testing for specified glioma, AML, myelodysplastic syndrome, or cholangiocarcinoma indications; used to select targeted therapy consistent with the labeled indication.

    KIT D816V, KMT2A, or MET testing

    Covered when applicable criteria are met.

    KIT D816V testing for aggressive systemic mastocytosis; KMT2A testing for relapsed or refractory AML; or MET exon 14 skipping testing for metastatic NSCLC, each used to select the corresponding targeted therapy.

    Mismatch repair/MSI, NTRK, PDGFRA, PDGFRB, or PIK3CA testing

    Covered when applicable criteria are met.

    Mismatch repair/MSI, NTRK, PDGFRA, PDGFRB, or PIK3CA testing for the specified advanced or metastatic cancers to select labeled therapy.

    PD-L1, KRAS/NRAS, RET, ROS1, TP53, or TMB testing

    Covered when applicable criteria are met.

    PD-L1, KRAS/NRAS, RET, ROS1, TP53, or TMB testing for the specified cancers and treatment-selection indications, with applicable FDA-label and NCCN requirements.

    Plasma ALK and BRAF testing

    Covered when applicable criteria are met; plasma is an alternative to tissue biopsy.

    FDA-approved companion diagnostic plasma testing for ALK rearrangements in NSCLC or BRAF V600E in metastatic colorectal cancer or NSCLC, used to select labeled therapy.

    ALK plasma ctDNA testing

    Covered when applicable criteria are met.

    Plasma ctDNA ALK rearrangement testing in NSCLC using an FDA-approved companion diagnostic to select FDA-approved ALK inhibitor therapy; may be used as an alternative to tissue biopsy.

    Liquid biopsy testing for specified biomarkers

    Covered when applicable criteria are met.

    Liquid biopsy testing for BRAF V600E, BRCA1/2, EGFR, ESR1, ATM, or other specified somatic biomarkers in the listed advanced or metastatic cancers, with applicable disease, timing, tissue-feasibility, treatment-selection, and FDA-label requirements.

    Liquid biopsy testing for MET, NTRK, PIK3CA, KRAS, ROS1, and insufficient tissue

    Covered when applicable criteria are met.

    Liquid biopsy testing for MET exon 14 skipping, NTRK fusions, PIK3CA, KRAS, or ROS1, or plasma testing for a tissue-based driver variant when tissue is insufficient, limited to the stated biomarker and therapy criteria.

    Biomarker testing in advanced or metastatic cancer

    Testing is supported for patients who meet the described cancer and treatment-selection conditions.

    Unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer; patient is being considered for an FDA-approved targeted therapy consistent with its label; therapy has an NCCN recommendation of 2A or higher.

    ALK rearrangements or fusions in NSCLC

    Covered when used to identify the indicated biomarker for treatment selection.

    Testing identifies an ALK rearrangement or fusion in NSCLC for selection of ALK-directed therapy.

    California statutory biomarker testing purposes

    California law requires coverage when prescribed for the specified clinical purposes.

    Biomarker testing is prescribed to diagnose, treat, appropriately manage, or provide ongoing monitoring of an enrollee's disease or condition to guide treatment decisions.

    AML companion diagnostic testing

    Covered when applicable criteria are met.

    AML is assessed using peripheral blood or bone marrow; IDH1, IDH2, or KMT2A companion diagnostic testing is used to select associated targeted treatment.

    Aggressive systemic mastocytosis KIT testing

    Covered when BOTH criteria are met.

    Aggressive systemic mastocytosis is assessed using bone; KIT D816V testing is used to select imatinib mesylate.

    Anaplastic thyroid cancer BRAF testing

    Covered when applicable criteria are met.

    Anaplastic thyroid cancer is assessed using tumor tissue; BRAF V600E testing is used to select dabrafenib with trametinib.

    Astrocytoma and oligodendroglioma testing

    Covered when applicable criteria are met.

    Astrocytoma or oligodendroglioma is assessed using tumor tissue; IDH1/IDH2 testing is used to select targeted treatment.

    B-cell chronic lymphocytic leukemia TP53 testing

    Covered when applicable criteria are met.

    B-cell chronic lymphocytic leukemia is assessed using peripheral blood; TP53 deletion of chromosome 17p testing is used to select venetoclax.

    Biliary tract cancer testing

    Covered when applicable criteria are met.

    Biliary tract cancer, including gallbladder, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma, is assessed using tissue for ERBB2/HER2 or FGFR2 alterations to select associated targeted treatment.

    Breast cancer testing

    Covered when applicable criteria are met.

    Breast cancer testing using plasma, tissue, or whole blood identifies PIK3CA, ESR1, ERBB2/HER2, AKT1, PTEN, or BRCA1/BRCA2 alterations or expression for associated treatment selection.

    Cervical cancer testing

    Covered when applicable criteria are met.

    Cervical cancer is assessed using tissue PD-L1 testing; pembrolizumab selection requires PD-L1 CPS at least 1.

    Cholangiocarcinoma testing

    Covered when applicable criteria are met.

    Cholangiocarcinoma is assessed using tissue FGFR2 testing to identify eligible alterations for targeted treatment.

    Chronic myeloid leukemia testing

    Covered when applicable criteria are met.

    Chronic myeloid leukemia is assessed using BCR-ABL testing to select associated therapy.

    Breast cancer HER2 and BRCA testing

    Covered when applicable criteria are met.

    Breast cancer testing identifies HER2 protein expression or BRCA1/BRCA2 mutations for associated FDA-approved therapy.

    Cervical cancer PD-L1 testing

    Covered when applicable criteria are met.

    Cervical cancer tissue PD-L1 testing is used to select pembrolizumab when PD-L1 CPS is at least 1.

    Cholangiocarcinoma FGFR2 testing

    Covered when applicable criteria are met.

    Cholangiocarcinoma tissue testing identifies FGFR2 fusions or select rearrangements for targeted treatment.

    Colorectal cancer KRAS, NRAS, BRAF, and RAS testing

    Covered when applicable criteria are met.

    Metastatic colorectal cancer testing evaluates KRAS, NRAS, BRAF, and related RAS alterations to select FDA-approved therapy.

    Colorectal cancer MSI-H, dMMR, KRAS, and NRAS testing

    Covered when applicable criteria are met.

    Colorectal cancer testing evaluates MSI-H, mismatch-repair deficiency, KRAS, and NRAS using listed tissue or matched blood/saliva assays for treatment selection.

    Endometrial carcinoma and gynecologic cancer testing

    Covered when applicable criteria are met.

    Endometrial carcinoma testing evaluates MSI or mismatch-repair status; related gynecologic cancer testing evaluates FOLR1 for treatment selection.

    Esophageal squamous cell carcinoma PD-L1 testing

    Covered when applicable criteria are met.

    Esophageal squamous cell carcinoma tissue PD-L1 testing is used to select pembrolizumab.

    Follicular lymphoma EZH2 testing

    Covered when applicable criteria are met.

    Follicular lymphoma tumor-tissue EZH2 testing evaluates specified EZH2 variants for selection of tazemetostat.

    Gastric and gastroesophageal cancer HER2 testing

    Covered when applicable criteria are met.

    Gastric or gastroesophageal cancer tissue testing evaluates HER2 amplification or protein overexpression for selection of trastuzumab-based therapy.

    Gastric or gastroesophageal junction PD-L1 and CLDN18 testing

    Covered when applicable criteria are met.

    Gastric or gastroesophageal junction adenocarcinoma tissue testing evaluates PD-L1 and CLDN18; listed PD-L1 use includes CPS at least 1 and CLDN18 testing identifies protein expression.

    Plasma ALK testing in NSCLC

    Covered when applicable criteria are met.

    Plasma ALK rearrangement testing in NSCLC uses the listed FDA-approved diagnostic to support Alecensa treatment selection.

    NSCLC ALK companion diagnostic testing

    Covered when applicable criteria are met.

    NSCLC has an ALK rearrangement identified by a listed companion diagnostic assay, supporting Alecensa, Xalkori, or Zykadia.

    NSCLC actionable molecular alteration or PD-L1 testing

    Covered when applicable criteria are met.

    NSCLC has an actionable EGFR, KRAS, ERBB2, MET, BRAF, ROS1, or RET alteration, or PD-L1 expression, identified by an FDA-approved assay for associated treatment selection.

    Ventana ALK D5F3 CDx testing

    Covered when applicable criteria are met.

    NSCLC ALK biomarker testing uses the Ventana ALK (D5F3) CDx Assay to detect ALK protein expression for associated ALK inhibitor treatment.

    Vysis ALK Break Apart FISH testing

    Covered when applicable criteria are met.

    NSCLC ALK gene rearrangement testing uses the Vysis ALK Break Apart FISH Probe Kit for associated ALK inhibitor treatment.

    Molecular testing for FDA-approved targeted therapies

    Covered when applicable criteria are met.

    Tumor-tissue or ctDNA testing is performed for unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer when an FDA-approved targeted therapy is being considered consistently with its labeled indication and has an NCCN recommendation of 2A or higher.

    Fusion testing for advanced solid tumors

    Covered when applicable criteria are met.

    Fusion testing is performed for advanced or metastatic solid tumors when a fusion-targeted therapy is approved for the disease; other fusion testing is recommended when large-panel DNA sequencing identifies no oncogenic driver alteration.

    Routine ESR1 testing in metastatic breast cancer

    Covered when applicable criteria are met.

    Routine ESR1 mutation testing is performed at recurrence or progression in estrogen receptor-positive, HER2-negative metastatic breast cancer receiving endocrine therapy, with or without a CDK4/6 inhibitor; blood or tissue from progression is used, with blood-based ctDNA preferred.

    Germline and somatic testing in metastatic castration-resistant prostate cancer

    Covered when applicable criteria are met.

    In metastatic castration-resistant prostate cancer, germline and somatic testing identifies DNA repair deficiency, MSI status, TMB, and other mutations that may inform prognosis, familial cancer risk, and targeted therapy.

    Coding and Companion Diagnostic Identifiers

    PLA Codes Listed for Companion Diagnostic TestingHCPCS
    0023PLA Code for the LeukoStrat CDx FLT3 Mutation Assay
    PLA CodesHCPCS
    0022UPLA code listed for Oncomine Dx Target Test
    0239UPLA code listed for Guardant360 CDx
    0326UPLA code listed for Guardant360 CDx
    0037PLA code listed for FoundationOne CDx and related breast cancer assays
    0037UPLA code listed for FoundationOne CDx and related breast cancer assays
    0211UPLA code listed for Caris Seek (MCS)
    0155UPLA code listed for the therascreen PIK3CA RGQ PCR Kit
    0177UPLA code listed for the therascreen PIK3CA RGQ PCR Kit and related entries
    FDA regulatory and laboratory identifiersmixed
    BLA 761139FDA biologics license application identifier for trastuzumab deruxtecan-nxki
    NDA 208558FDA new drug application identifier for Lynparza (olaparib)
    P140020/S012PMA supplement identifier for BRACAnalysis CDx
    P140020/S015PMA supplement identifier for BRACAnalysis CDx
    BLA 125514FDA biologics license application identifier for Keytruda (pembrolizumab)
    P150013/S009PMA supplement identifier for PD-L1 IHC 22C3 pharmDx
    NDA 213736FDA new drug application identifier for Pemazyre (pemigatinib)
    P170019/S013PMA supplement identifier for FoundationOne CDx
    P160045/S028PMA supplement identifier for the listed chronic myeloid testing assay
    K173492FDA clearance identifier for the listed BCR-ABL fusion assay
    1–10 of 37
    1/4
    NSCLC Plasma ALK Diagnostic Identifiersmixed
    P200006FDA PMA approval identifier listed for the plasma ALK diagnostic
    UPLA code listed for the plasma ALK diagnostic
    FDA regulatory and PLA identifiers for listed companion diagnostic assaysmixed
    P200010FDA PMA identifier for Guardant360 CDx, including NSCLC plasma indications
    P200010/S001FDA supplement identifier for Guardant360 CDx
    P200010/S002FDA supplement identifier for Guardant360 CDx
    P200010/S008FDA supplement identifier for Guardant360 CDx
    P200010/S011FDA supplement identifier for FoundationOne Liquid CDx
    P200010/S014FDA supplement identifier for FoundationOne Liquid CDx
    P200010/S019FDA supplement identifier for Oncomine Dx Target Test
    P200010/S027FDA supplement identifier for Oncomine Dx Target Test
    P200010/S031FDA supplement identifier for Oncomine Dx Target Test
    P200010/S035FDA supplement identifier for Oncomine Dx Target Test
    1–10 of 29
    1/3
    Associated FDA drug application identifiersmixed
    NDA 208434Alecensa (alectinib)
    NDA 202570Xalkori (crizotinib)
    NDA 211225Zykadia (ceritinib)
    NDA 208772Brigatinib
    NDA 202806Tafinlar (dabrafenib)
    NDA 204114Mekinist (trametinib)
    NDA 208065Tagrisso (osimertinib)
    NDA 201292Gilotrif (afatinib)
    NDA 206995Iressa (gefitinib)
    NDA 214665Lumakras (sotorasib)
    1–10 of 19
    1/2
    PLA codes for companion diagnostic testingCPT
    0037UPLA code listed for FoundationOne CDx solid-tumor tissue diagnostic testing.
    PLA codes for companion diagnostic testingCPT
    0211UPLA code listed for MI Cancer Seek (MCS) solid-tumor tissue diagnostic testing.
    PLA codes for companion diagnostic testingCPT
    0543PLA code shown for TruSight Oncology diagnostic testing.
    PLA codes for companion diagnostic testingCPT
    0022UPLA code listed for Oncomine Dx Target Test thyroid cancer tissue testing.
    PLA codes for companion diagnostic testingCPT
    0154UPLA code listed for therascreen FGFR RGQ RT-PCR Kit urothelial cancer testing.
    Molecular testing codesCPT
    0023UOncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin.
    Molecular testing codesCPT
    0037UTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden; includes FoundationOne CDx (F1CDx).
    Molecular testing codesCPT
    0040UBCR/ABL1 [t(9;22)] translocation analysis, major breakpoint, quantitative; includes MRDx BCR-ABL Test.
    0111UOncology (colon cancer), targeted KRAS codons 12, 13, and 61 and NRAS codons 12, 13, and 61 gene analysis utilizing formalin-fixed paraffin-embedded tissue; includes Praxis Extended RAS Panel.
    Molecular and genetic testing codesCPT
    0040UBCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative; includes MRDx BCR-ABL Test, MolecularMD, MolecularMD Oncology
    0111UDetection or non-detection of FLT3 mutation and indication for or
    0154UOncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis, utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status
    0155UOncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene analysis
    HER2-low expression
    Expression categoryHER2-low expression
    IHC resultIHC 1+
    Alternative resultIHC 2+/ISH
    HER2-ultralow expression
    Expression categoryHER2-ultralow expression
    IHC resultIHC 0
    Required findingMembrane staining
    HER2 protein overexpression
    Expression categoryHER2 protein overexpression
    Testing methodImmunohistochemistry (IHC)
    ThresholdIHC 3+
    PD-L1 expression
    BiomarkerPD-L1 expression
    Scoring methodCombined Positive Score (CPS)
    ThresholdCPS ≥ 1
    Biomarker expression thresholds
    PD-L1 thresholdCombined Positive Score (CPS) ≥ 1
    Protein assessmentProtein expression may be reported using biomarker-specific scoring methods
    Other result typesGene mutations, gene amplification, MSI-H, dMMR, and specified wild-type status
    PD-L1 tumor proportion score for Keytruda
    DrugKeytruda (pembrolizumab)
    BiomarkerPD-L1 protein expression
    ThresholdTumor Proportion Score (TPS) ≥ 1%
    PD-L1 tumor proportion score for Libtayo
    DrugLibtayo (cemiplimab-rwlc)
    BiomarkerPD-L1 protein expression
    ThresholdTumor Proportion Score (TPS) ≥ 50%
    PD-L1 tumor cell staining for Opdivo plus Yervoy
    RegimenOpdivo (nivolumab) plus Yervoy (ipilimumab)
    BiomarkerPD-L1 protein expression
    ThresholdTumor cell staining ≥1%
    Tumor mutational burden
    BiomarkerTumor mutational burden (TMB)
    MeasurementMutations per megabase
    ThresholdTMB ≥ 10 mutations per megabase
    PD-L1 expression in triple-negative breast cancer
    Cancer typeTriple-negative breast cancer
    BiomarkerPD-L1 protein expression
    ThresholdCombined Positive Score (CPS) ≥ 10
    PD-L1 expression in urothelial carcinoma
    Cancer typeUrothelial carcinoma
    BiomarkerPD-L1-stained tumor-infiltrating immune cells
    ThresholdCells cover ≥ 5% of the tumor area

    Provider Actions and Review Requirements

    Documentation Required

    Confirm Clinical Indication and Tissue Status

    Confirm the clinical indication and specimen strategy before ordering testing. Tissue-based testing is generally tied to the specified advanced, metastatic, recurrent, relapsed, refractory, or otherwise listed cancer indication; plasma testing is an alternative only where the policy permits it, such as when tissue is insufficient or a biopsy is not feasible and follow-up tissue testing is planned when applicable.

    • Document the diagnosis, disease stage, progression status, and relevant histology.
    • Document whether adequate formalin-fixed paraffin-embedded tissue is available and, when plasma testing is used, why tissue testing is not feasible or sufficient.
    • For plasma testing under the tissue-insufficiency provision, plan follow-up tissue-based analysis if no driver variant is identified.

    Unsupported block type: billing_rule

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: billing_rule

    Background

    This policy addresses genetic and molecular biomarker testing used to select treatment in patients with unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer. Covered testing may use tumor tissue, blood, bone marrow, or plasma circulating tumor DNA, depending on the biomarker-specific criteria. In general, the test result must guide selection of an FDA-approved targeted therapy or other specified treatment used consistently with its FDA-approved label; several covered indications also reference an NCCN recommendation of 2A or higher.

    The policy includes somatic tumor testing, selected germline BRCA1/BRCA2 testing, blood or bone marrow testing, companion diagnostic testing, and defined liquid-biopsy alternatives. It does not address germline testing for inherited cancer risk, and expanded-panel or broader liquid-biopsy services may be addressed under related policies.

    Definitions

    TRK inhibitor therapy
    TherapyTRK inhibitor therapy
    TargetTumors containing neurotrophic receptor tyrosine kinase gene fusions
    ExamplesLarotrectinib or entrectinib
    Liquid biopsy
    SpecimenPlasma
    AnalyteCirculating tumor DNA (ctDNA)
    RoleAn alternative to tissue biopsy
    NCCN-recommended immune checkpoint inhibitors
    Therapy classImmune checkpoint inhibitors
    Recommendation sourceNational Comprehensive Cancer Network (NCCN)
    Recommendation levelCategory 2A or higher
    Targeted therapy
    Therapy typePrecision or personalized cancer treatment
    MechanismDrugs interact with or block synthesis of specific cellular components characteristic of the disease
    PurposeStops or interrupts the biochemical dysfunction involved in disease progression
    Genetic therapy
    Therapy typeGenetic therapy
    ApproachTechniques and strategies that include coding sequences
    PurposeTransform or modify cells to treat or reverse disease conditions
    Paired genetic testing
    Tumor testingAssesses acquired somatic changes in tumor tissue
    Paired testingSequences tumor and normal tissue together
    Clinical valueHelps distinguish somatic findings from inherited germline changes and may identify cancer risk
    Tissue-based and liquid biopsy testing
    Tissue biopsyAssesses cancer DNA in sampled tissue
    Liquid biopsyAssesses cancer DNA and non-cancer DNA in a blood sample
    Clinical purposeIdentifies options for genome-informed treatment
    Pathogenic
    ClassificationPathogenic
    MeaningA disease-causing change in the DNA sequence
    UseACMG-AMP standard terminology for variant classification
    Likely pathogenic
    ClassificationLikely pathogenic
    MeaningA likely disease-causing change in the DNA sequence
    UseACMG-AMP standard terminology for variant classification
    Variant of uncertain significance
    ClassificationVariant of uncertain significance
    MeaningA change in DNA sequence with uncertain effects on disease
    UseACMG-AMP standard terminology for variant classification
    Likely benign
    ClassificationLikely benign
    MeaningA likely benign change in the DNA sequence
    UseACMG-AMP standard terminology for variant classification
    Benign
    ClassificationBenign
    MeaningA benign change in the DNA sequence
    UseACMG-AMP standard terminology for variant classification
    Genetic counseling
    ServiceGenetic counseling
    PurposeHelps individuals understand the potential benefits and harms of genetic testing
    Additional topicsRisk factors and possible effects of results on family members
    Liquid biopsy
    Test typeCirculating tumor DNA testing
    Alternative nameLiquid biopsy
    SpecimenBlood-derived circulating tumor DNA
    Companion diagnostic test
    Test typeCompanion diagnostic test
    AssociationListed with a targeted treatment and biomarker
    PurposeIdentifies patients who may be appropriate for the treatment
    MSI-H
    AbbreviationMSI-H
    Expanded termMicrosatellite instability-high
    Clinical relevanceA molecular signature used in listed cancer treatment decisions
    dMMR
    AbbreviationdMMR
    Expanded termDeficient mismatch repair
    Proteins assessedMLH1, PMS2, MSH2, and MSH6
    KRAS wild-type
    StatusKRAS wild-type
    MeaningAbsence of specified KRAS mutations
    Assay regionsCodons 12 and 13 or exons 2, 3, and 4, as specified for the assay
    dMMR
    AbbreviationdMMR
    Expanded termMismatch repair deficient
    UseListed as a biomarker abbreviation in the companion-diagnostic table
    MSI-H
    AbbreviationMSI-H
    Expanded termMicrosatellite instability-high
    UseListed as a biomarker abbreviation in the companion-diagnostic table
    TMB
    AbbreviationTMB
    Expanded termTumor mutational burden
    UseListed as a biomarker abbreviation in the companion-diagnostic table
    NDA
    AbbreviationNDA
    Expanded termNew drug application
    ContextFDA drug application identifier
    BLA
    AbbreviationBLA
    Expanded termBiologics license application
    ContextFDA biologics application identifier
    PLA code
    Code typePLA code
    PurposeCode for the diagnostic test
    Coding noteCPT codes for genes are listed in the coding table
    EML4-ALK fusion
    FusionEML4-ALK fusion
    FormationResults from an inversion within the short arm of chromosome 2
    EffectAssociated with constitutive tyrosine kinase activity in NSCLC
    EGFR sensitizing variants
    VariantsEGFR exon 19 deletions and exon 21 L858R substitution
    Variant typeSomatic EGFR variants
    Clinical associationAssociated with sensitivity to EGFR tyrosine kinase inhibitors
    EGFR T790M
    VariantEGFR T790M
    Variant typeSecondary EGFR resistance variant
    Molecular changeSubstitution of methionine for threonine at position 790 on exon 20
    Homologous recombination deficiency
    AbbreviationHRD
    MeaningLoss or impairment of homologous recombination repair capacity
    ConsequenceAccumulation of genomic errors and genomic instability
    Mismatch repair deficiency
    AbbreviationdMMR
    MeaningAlterations in genes responsible for correcting DNA replication errors
    Clinical associationdMMR tumors generally have a high tumor mutational load and may respond to anti-PD-L1 immunotherapy
    Microsatellite instability-high
    AbbreviationMSI-H
    MeaningA high level of instability in microsatellite biomarkers
    DefinitionInstability in at least 2 of 5 biomarkers or in more than 30% of tested biomarkers, depending on the panel
    NTRK gene fusion testing
    Test targetNeurotrophic receptor tyrosine kinase gene fusions
    MethodsNext-generation sequencing, reverse-transcription PCR, fluorescence in situ hybridization, or immunohistochemistry
    PurposeIdentify fusions that may support targeted therapy selection
    Tumor mutational burden
    AbbreviationTMB
    MeaningMeasure of gene mutations within cancer cells
    Assessment methodsWhole-exome sequencing or targeted next-generation sequencing panels
    Circulating tumor DNA
    AbbreviationctDNA
    SourceTumor-derived component of cell-free DNA in blood
    UseGenomic characterization of the tumor
    Clinically useful test
    Test characteristicClinically useful test
    PurposeProvides information for a clinical management decision
    Outcome standardImproves the net health outcome
    Liquid biopsy
    SpecimenLiquid biopsy specimen
    AnalytesCirculating tumor DNA or plasma cell-free DNA
    PurposeMolecular sequencing
    NGS
    AbbreviationNGS
    Expanded termNext-generation sequencing
    PurposeDiagnostic laboratory testing to identify cancer-associated genetic alterations
    Fusion testing
    Test typeFusion testing
    Method focusGenomic rearrangement testing
    TargetsGene fusions or exon-skipping variants that may support targeted therapy selection

    Eligibility Requirements

    For germline BRCA1/BRCA2 testing, document the applicable cancer diagnosis and the clinical features supporting eligibility. Relevant covered populations include individuals with HER2-negative metastatic or early-stage high-risk breast cancer, metastatic castrate-resistant prostate cancer, or advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer when testing is used to select PARP inhibitor therapy.

    Family history may support assessment of inherited BRCA risk. Patterns of concern include early-onset or bilateral breast cancer, male breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Formal genetic counseling is recommended in most cases when testing for an inherited condition is being considered.

    Eligibility may depend on the patient’s prior treatment and the timing of testing. Examples include progression after at least one line of endocrine therapy for ESR1 testing, at least two prior systemic therapies for EZH2 testing, prior treatment for FGFR2 testing, progression during or after at least one line of platinum-containing chemotherapy for FGFR3 testing, and one to three prior systemic regimens for FOLR1 testing.

    For ESR1, tissue testing is addressed as an alternative to liquid biopsy in estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer after endocrine-therapy progression. For plasma EGFR T790M testing, new tissue biopsy must not be feasible because of insufficient tissue, lack of a biopsy-amenable lesion, or inability to undergo biopsy. When plasma testing is performed because tissue is insufficient, follow-up tissue-based analysis must be planned if no driver variant is identified.

    Not Covered and Investigational Uses

    BRAF testing outside the specified pediatric low-grade glioma indication is not covered as medically necessary. Testing for BRAF V600 variants or BRAF fusion rearrangements to select targeted treatment is limited to individuals with relapsed or refractory pediatric low-grade glioma when the result will be used to select tovorafenib. Testing for other glioma populations, including glioma outside that relapsed or refractory pediatric low-grade glioma setting, is considered investigational.